| Literature DB >> 35815064 |
Ebtesam Sobhanie1, Foad Salehnia2, Guobao Xu3, Yalda Hamidipanah4, Shayesteh Arshian4, Ali Firoozbakhtian1, Morteza Hosseini1, Mohammad Reza Ganjali4,5, Saima Hanif6.
Abstract
Researchers are constantly looking to find new techniques of virus detection that are sensitive, cost-effective, and accurate. Additionally, they can be used as a point-of-care (POC) tool due to the fact that the populace is growing at a quick tempo, and epidemics are materializing greater often than ever. Electrochemiluminescence-based (ECL) biosensors for the detection of viruses have become one of the most quickly developing sensors in this field. Thus, we here focus on recent trends and developments of these sensors with regard to virus detection. Also, quantitative analysis of various viruses (e.g., Influenza virus, SARS-CoV-2, HIV, HPV, Hepatitis virus, and Zika virus) with a specific interest in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was introduced from the perspective of the biomarker and the biological receptor immobilized on the ECL-based sensors, such as nucleic acids-based, immunosensors, and other affinity ECL biosensors.Entities:
Keywords: COVID-19; Electrochemiluminescence; Genosensors; HIV; HPV; Hepatits B; Immunosensors; Influenza; Respiratory virus; SARS-CoV-2; Virus detection; Zika virus
Year: 2022 PMID: 35815064 PMCID: PMC9254503 DOI: 10.1016/j.trac.2022.116727
Source DB: PubMed Journal: Trends Analyt Chem ISSN: 0165-9936 Impact factor: 14.908
Scheme 1Electrochemiluminescence biosensors for human virus detection.
Fig. 1Illustration of the immunomagnetic based ECL immunosensor for H9N2 AIV detection [45].
Fig. 2A: Schematic of the double amplification strategy based on DNA tetrahedral ratiometric ECL-based biosensor for the assay SARS-CoV-2 RdRp gene [53]. B: Schematic Illustration of (a) Preparation of Au@Ti3C2@PEI-Ru(dcbpy)32+ Nanocomposites; (b) based on Au@Ti3C2@PEI-Ru(dcbpy)32+ Nanocomposites ECL Biosensor Detection of the SARS-CoV-2 RdRp Gene Combined Unipedal DNA Walker Amplification Strategy [55].
Fig. 3A: Schematic of the pH-induced biosensor for the detection of SARS-CoV-2 RdRp gene [59]. B: Scheme of the ECL DNA biosensor development [60].
Summary of various biosensors for respiratory virus detection.
| Platform | ECL Luminophor | Type of Virus detection | target | Linear ranges | ECL pathway | LOD | matrix | Ref | |
|---|---|---|---|---|---|---|---|---|---|
| Gold electrode | Ru complex | Immunosensor | Hemagglutinin | 3 × 10−14 to 2 × 10−12 g mL−1 | Coreactant | 10−14 | [ | ||
| Au electrode/DTPA/HT binary SAMs | Ru complex | Immunosensor | influenza virus A (H1N1) | 2.7 × 102 to 2.7 × 103 PFU mL−1 | Coreactant | Not determined | Commercial | [ | |
| Au nanostructures (AGN)/ITO | Ru complex | Immunosensor | H9N2 avian influenza virus | 25 fg mL−1 to 25 ng mL−1 | Coreactant | 14 fg mL−1 | chicken liver, serum, and lung | [ | |
| PEI-Ru@Ti3C2@AuNPs | g-C3N4 | Genosensor | SARS-CoV-2 | 10 aM to 10 pM | Coreactant | 7.8 aM | human serum | [ | |
| Au@Ti3C2@PEI-Ru(dcbpy)32+ | Ru complex | Genosensor | SARS-CoV-2 | 1 fM to 100 pM | Coreactant | 0.21 fM | human serum | [ | |
| DNA tetrahedron | Ru complex | Genosensor | SARS-CoV-2 | 1 fM to 100 pM | Coreactant | 2.67 fM | human serum | [ | |
| PEI-Ru@Ti3C2@AuNPs | Ru complex | Genosensor | SARS-CoV-2 | 0 aM | Coreactant | 12.8 aM | pharyngeal swabs samples | [ | |
| Au-g-C3N4/DNA tetrahedron | Ru complex | Genosensor | SARS-CoV-2 | 10 aM to 10 pM | Coreactant | 43.70 aM | pharyngeal swabs samples | [ | |
| AuNMs and CDs | Ru complex | Genosensor | SARS-CoV-2 | 50.0 fM to 100.0 nM | Coreactant | 514 aM | human serum | [ | |
| Gold electrode | Ru complex | Genosensor | SARS-CoV-2 ORF1 gene | 0.1 fM to10 μM | Coreactant | 0.1 fM | simulation samples(saliva and urine) | [ | |
| modified GCE | PDP polymer nanoparticles | Immunosensor | SARS-CoV-2 | 50 fg mL−1 -1.0 ng mL−1 | Coreactant | 22 fg mL−1 | Serum Sample | [ | |
Fig. 4Scheme of the ECL biosensing based on 3D CdSe QDs-DNA nanonetwork- SnO2 nanoflower coupled with DNA walker multiple amplification for HIV detection [66].
Summary of various biosensors for HIV and HPV detection.
| Platform | ECL luminophor | Type of Virus detection | ECL pathway | Linear ranges | LOD | Matrix | Ref |
|---|---|---|---|---|---|---|---|
| ECL | RGO@Au composite | HIV Immunosensor | coreactant | 10 ng mL−1 | 1 ng mL−1 | serum samples | [ |
| ECL | Ti3C2Tx MXenes modified ZIF-8 | HIV aptasensor | coreactant | 1 nM | 0.3 fM | Serum sample | [ |
| ECL | CdSe QDs-DNA nano-network | HIV Genosensor | coreactant | 0.5 μM to 5 fM, | 2.4 fM | serum samples | [ |
| ECL | CdSe/ZnS quantum dots @poly(styrene/acrylamide) nanospheres | HIV Genosensor | coreactant | 50 nM to 0.5 pM | 39.81 fM | [ | |
| ECL | EuS NCs | HIV Genosensor | coreactant | 0.3 nM to 0.3 fM | 0.3 fM | Serum sample | [ |
| ECL | AuNCs | HPV Genosensor | coreactant | 0.1 fM to 10 nM | 0.06 fM | Clinical samples | [ |
| ECL | Ru(phen)32+ | HPV Genosensor | coreactant | 1 fM to 15 pM | 7.6 fM | Clinical samples | [ |
| ECL | AuNCs | HPV Genosensor | coreactant | 10 nM to 1pM | 0.48 pM | Blood sample | [ |
Fig. 5A: The HCR-based sensing process and distance-dependent plasmon-enhanced ECL [77] BB. Schematic of the ECL-based biosensor based on GQDs combining with endonuclease cleavage and bidentate chelation [79], C: The mechanism illustration of the increased ECL by antenna effect and dual enhancement effect of CoS2 TSNBs [80].
Summary of various biosensors for hepatitis virus detection.
| Platform | ECL Luminophor | Type of Virus detection | target | Linear ranges | ECL pathway | LOD | matrix | Ref |
|---|---|---|---|---|---|---|---|---|
| Eu-MOF (EuBTC) | immunosensor | procalcitonin (PCT) | (10 fg mL−1-100 ng mL−1) | Coreactant | 3.65 fg mL−1 | [ | ||
| rGO-TEPA | Au@Pt Nanoparticles | immunosensor | HBsAg | 0.25 pg mL−1 to 400 ng mL−1 | Coreactant | 0.08 | human serum | [ |
| MoS2 nanosheets | sulfur doped boron nitrogen QDs (S-BN QDs) | Genosensor | hepatitis C virus (HCV) gene | 0.5 pM to 1 nM | Coreactant | 0.17 pM | human serum | [ |
| polymer material | [Ru(bpy)3]2+ -Polymer | Genosensor | HBsAg gene of the Hepatitis B virus | 102 aM–106 aM | Coreactant | 100 aM | serum | [ |
| Graphene nano sheets | CdTe QDs | Genosensor | DNA HBV and DNA HCV | 0.0005–0.5 nM | Coreactant | 0.082 pM and 0.34 pM | human serum | [ |
| DTC-DNA/MCH/ethylenedianmine/GQDs | graphene quantum dots (GQDs) | Genosensor | hepatitis C virus- | 5 fM to 100 pM | Coreatant | 0.45 fM | Not mentioned | [ |
| paper-based BPE | [Ru(bpy)3]2+ | Genosensor | hepatitis B virus gene (HBV) | 0.2 to 100 fM | Coreactant | 0.2 fM | Serum | [ |
| GCE/ABEI-PEI/ternary NCs/CS | N-(aminobutyl)-N-(ethylisoluminol) (ABEI) | Genosensor | HBV-related DNA | 0.01–100 fM | Coreactant | down to 65 aM | human serum | [ |
| poly(aniline-luminol)-MWCNTs | Luminol | Genosensor | hepatitis B virus | 10−16–10−7 M | Coreactant | 2.4 × 10−17 M | Serum | [ |
| Au electrode (CHI101) | (phen)2dppz]2+ complex | Genosensor | hepatitis B virus gene (HBV) | 0–0.75–0.017 cps μL−1 | Coreactant | 0.05 cps μL−1 | genome extracted from real samples | [ |
Summary of various biosensors for zika virus detection.
| Platform | Type of Virus detection | ECL luminophor | ECL pathway | Linear ranges | LOD | Matrix | Ref |
|---|---|---|---|---|---|---|---|
| polystyrene beads (PSB) | immunosensor | Ru(bpy)3+2 | Coreactant | 0–104 PFU | 1 PFU in 100 μl | human plasma, human urine. | [ |
| Fe-MIL-88 MOFs | genosensor | AuNPs&g-C3N4@Zr-MOG | Coreactant | 0.3 nM to 3 μM | 0.1 nM | Human serum | [ |
| SiO2 microspheres | immunosensor | CdS QDs | Coreactant | 1.0 fg mL−1 to 1.0 ng mL−1 | 0.3 fg mL−1 | Human serum | [ |
Fig. 6A. Schematic illustration of the construction process of the proposed ECL sensing platform [88]. B. Preparation of the activation of MPA@CdS QDs (A), the fabrication process of the proposed ECL immunosensor (B) and ECL mechanism of A-CdS QDs (C) [89].